Asking directly, because I could not find a straight answer: Why catalogue breadth is not evidence of anything — what changed since
What changes if the standard account of catalogue breadth is wrong? I ask because I have been treating it as settled and I noticed this week that I could not say why.
Working through the consequences rather than the evidence, since others here are better placed on the evidence.
Worth separating two things that the opening post runs together.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Noting that the question and the thing people usually mean by it are different.
Two people in this thread mean different things by catalogue breadth and are disagreeing about the definition while believing they are disagreeing about the facts. Worth pausing to define it.
Research use only, not approved for human use, and in this subcategory the compounds vary enormously in how much is known about them. It is worth establishing which end of that range a specific compound sits at before anything else.
This is the sort of exchange that makes the archive worth searching.
Post #4 and I disagree about the size of the effect, not about the direction.
Practical answer on catalogue breadth, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide whether the complicated explanation is needed. It usually is not.
Genuine question rather than a rhetorical one: has anyone here actually observed catalogue breadth, as opposed to read about it? The thread is long and I cannot tell.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
That is the shape of it. The detail is where I would expect to be corrected.
Building on post #6 rather than restating it.
A compound with no established assay is a compound where a certificate can say almost anything. That is not an accusation about anyone; it is a statement about what a document can carry.
I had written a reply contradicting post #7 and deleted it. Here is what survived.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Somebody will have a better source than mine, and I hope they post it.
Confirming post #11 from a second method, which matters more than confirming it from a second person.
How to research a compound with no human data: mechanistic plausibility is one input. Preclinical data is another. The honest position is that you are reasoning from theory, not from evidence, and the track record of such reasoning is unimpressive when tested against actual outcomes.
It is a small point and it changes the answer, which is an awkward combination.
I had read the opposite somewhere and cannot now find where, which tells me something.
Adding what did not work for me on catalogue breadth, since the failures never get written up and they are half the useful information.
Practical experience of catalogue breadth, offered as one case with the conditions stated, not as a general finding. Conditions first, because they are what make it interpretable.
Post #15 is right about the mechanism and I think understates the practical bit.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
I have left out the parts I could not verify.
On post #15 — agreed on the reasoning, with one qualification.
Why catalogue breadth is not evidence of anything: a supplier listing 500 compounds does not make the 450 untested ones likely to work. It makes them untested compounds with supplier pages.
This has been discussed before and I could not find the thread, so, again.
Reading a supplier's product description as a marketing document: that is exactly what it is. The hyperbole, the mechanism written as fact, the theoretical benefits stated as established benefits — all of that is marketing. Treat it as such and separate it from evidence where evidence exists.
It is worth checking rather than assuming, which costs nothing.
Anything in this subcategory with a published trial behind it should be discussed separately from anything without one. Mixing them produces a discussion where the confident claims come from the compounds with the least evidence.
The bit of catalogue breadth that nobody enjoys is that the answer changes depending on what you are trying to decide with it. Say what the decision is and the thread will converge.
Taking post #20 at face value and following it one step further.
Adding a reference point for catalogue breadth. Mine is a single case, collected without controls, and I am posting the method alongside it so it can be discounted appropriately.
Post #18 and I disagree about the size of the effect, not about the direction.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
The confident version of this sentence would be wrong, so here is the hedged one.
This subcategory exists because some people will research compounds outside the main groups discussed here. The standard of evidence and honesty about its limits applies to everything discussed, not just to approved drugs.
This follows post #24 rather than contradicting it.
A methods point on catalogue breadth rather than a substantive one: if the comparison is not like for like, the difference you are measuring is the difference in method.
The version of catalogue breadth that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and those conditions are where the interesting cases live.
Thymosin alpha-1 has a regulatory history in several jurisdictions and a real clinical literature, which puts it in a different evidential category from most of its neighbours here.
Coming back to post #27, because the follow-up matters more than the original answer.
PT-141 was developed from the same family with a different receptor profile, and it has a considerably better documented human evidence base than most compounds discussed in this subcategory.
Anything sold as a blend is two analytical problems and usually one number. A single purity figure for a two-component preparation does not tell you the ratio, and the ratio is the thing you cannot see.
That is the honest state of it as of this week.
Anything in this subcategory with a published trial behind it should be discussed separately from anything without one. Mixing them produces a discussion where the confident claims come from the compounds with the least evidence.
I checked the source rather than the summary, and they differ.